Evidence map›Paper›PMID 35813502›Full record

ArticleFrontiers in cellular neuroscience2022

Transcriptomic Profile of Blood-Brain Barrier Remodeling in Cerebral Amyloid Angiopathy.

Muyu Situ, Ali Francisco Citalan-Madrid, Svetlana M Stamatovic, Richard F Keep, Anuska V Andjelkovic

Open access · goldAbstract read
In one paragraph

Article in Frontiers in cellular neuroscience, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 1 pooled it
2.2field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 1 synthesis or guideline pooled it, 19 citations in OpenAlex.

  1. Pooled it
  2. Cerebral proteome adaptations to amyloid angiopathy are prevented by carbonic anhydrase inhibitors.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  3. Article
  4. Article
  5. Associations of cortical SPP1 and ITGAX with cognition and common neuropathologies in older adults.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Muyu SituNeuroscience Graduate Program, University of Michigan Medical School, Ann Arbor, MI, United States.
Ali Francisco Citalan-MadridDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, United States.
Svetlana M StamatovicDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, United States.
Richard F KeepDepartment of Neurosurgery, University of Michigan Medical School, Ann Arbor, MI, United States.
Anuska V AndjelkovicDepartment of Pathology, University of Michigan Medical School, Ann Arbor, MI, United States.
University of Michigan–Ann Arbor · US

Funding

Claudin Expression Profiles and Blood Brain Barrier in AgingRF1AG057928 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ANDJELKOVIC-ZOCHOWSKA, ANUSKA V. · 2017 to 2017
$2.3M
Connexin 43 and hemorrhagic complication in cerebral amyloid angiopathyRF1AG064957 · NIA · UNIVERSITY OF MICHIGAN AT ANN ARBOR · PI ANDJELKOVIC-ZOCHOWSKA, ANUSKA V. · 2019 to 2019
$2.3M
NIA NIH HHS RF1 AG057928NIA NIH HHS RF1 AG064957
6 · The paper itself

Abstract

Cerebral amyloid angiopathy (CAA) is a small vessel disease characterized by amyloid β (Aβ) peptide deposition within the walls of medium to small-caliber blood vessels, cerebral microhemorrhage, and blood-brain barrier (BBB) leakage. It is commonly associated with late-stage Alzheimer's disease. BBB dysfunction is indicated as a pathological substrate for CAA progression with hyperpermeability, enhancing the extravasation of plasma components and inducing neuroinflammation, further worsening BBB injury and contributing to cognitive decline. Although significant effort has been made in defining the gene mutations and risk factors involved in microvascular alterations with vascular dementia and Alzheimer's disease, the intra- and intercellular pathogenic mechanisms responsible for vascular hyperpermeability are still largely unknown. The present study aimed to elucidate the transcriptional profile of the cerebral microvessels (BBB) in a murine model with CAA vasculopathy to define potential causes and underlying mechanisms of BBB injury. A comprehensive RNA sequencing analysis was performed of CAA vasculopathy in Tg-SwDI mice at 6 and 18 months in comparison to age-matched wildtype controls to examine how age and amyloid accumulation impact the transcriptional signature of the BBB. Results indicate that Aβ has a critical role in triggering brain endothelial cell and BBB dysfunction in CAA vasculopathy, causing an intense proinflammatory response, impairing oxidative metabolism, altering the coagulation status of brain endothelial cells, and remodeling barrier properties. The proinflammatory response includes both adaptive and innate immunity, with pronounced induction of genes that regulate macrophage/microglial activation and chemokines/adhesion molecules that support T and B cell transmigration. Age has an important impact on the effects of Aβ, increasing the BBB injury in CAA vasculopathy. However, early inflammation, particularly microglia/macrophage activation and the mediators of B lymphocytes' activities are underlying processes of BBB hyperpermeability and cerebral microbleeds in the early stage of CAA vasculopathy. These findings reveal a specific profile of the CAA-associated BBB injury that leads to a full progression of CAA.

Indexed as

agingblood-brain barriercerebral amyloid angiopathyinflammationmicrobleedsmicrogliapermeabilityvasculopathy

Identifiers

PMID35813502
PMCPMC9257207
OpenAlexW4283375799

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.